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Abstract
Background—Inhaled alpha1-proteinase inhibitor (PI) is known to reduce neutrophil elastase 
burden in some patients with CF. This phase 2a study was designed to test inhaled Alpha-1 HC, a 
new aerosolized alpha1-PI formulation, in CF patients.
Methods—We performed a randomized, double-blind, placebo-controlled study and evaluated 
the safety of 100 or 200 mg of inhaled Alpha-1 HC once daily for 3 weeks in subjects with CF. 
Thirty adult subjects were randomized in a 2:1 ratio to receive Alpha-1 HC or placebo.
Results—Drug delivery was confirmed by a dose-dependent increase in the sputum alpha1-PI. 
Seven (20.0%) of the 35 adverse events in the 100-mg dose group, 3 (13.0%) of 23 in the 200-mg 
dose group, and 4 (14.3%) of 28 in the placebo group were drug-related in these subjects. One 
serious adverse event occurred in 1 subject within each group.
Conclusions—Alpha-1 HC inhalation was safe and well tolerated.
Introduction
Cystic fibrosis (CF) lung disease is characterized by viscous mucus, chronic respiratory 
infections, and a sustained exaggerated inflammatory response [1]. Airway recruitment of 
neutrophils causes airway tissue destruction and remodeling through excess release of 
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neutrophil elastase (NE) [2–4]. Endogenous alpha1-proteinase inhibitor (alpha1-PI), which 
inhibits NE activity, is overwhelmed by excess release of NE in patients with CF [2–5]. This 
protease/antiprotease imbalance results in a progressive decline in lung function, in part 
through airway remodeling [2, 3, 6]. There is no specific antiprotease treatment available for 
patients with CF [2, 7]. The potential protective function of alpha1-PI provides a strong 
rationale to develop chronic antiprotease therapies to control airways inflammation and 
tissue damage.
Human plasma-derived alpha1-PI has a well-established safety profile when administered 
intravenously in patients with alpha1-antitrypsin deficiency, a condition characterized by 
increased serine protease activation leading to early-stage emphysema [8–11]. Aerosolized 
delivery of alpha1-PI by inhalation permits delivery of drug to the site of active airway 
disease while limiting systemic exposure [12] and has been shown to reduce NE burden and 
inflammation in respiratory secretions of alpha1-antitrypsin–deficient patients [13–15]. In 
previous studies, aerosolized alpha1-PI has been found to be both safe and well tolerated in 
patients with CF [3, 6, 16–18]. However, an effective combination of delivery system and 
drug is required to efficiently deposit aerosolized alpha1-PI in a sufficient dose at the site of 
CF lung disease. The AKITA2® APIXNEB™ (Vectura Group plc, Chippenham, United 
Kingdom) electronically regulated nebulizer system increases drug deposition compared 
with older nebulizer systems and allows for accurate dosing that is independent of lung 
function impairment. This is achieved by customizing and controlling the patient’s breathing 
pattern [16]. Therefore, it is hypothesized that the combination of a well-tolerated alpha1-PI 
preparation and an electronically regulated nebulizer system may provide improved 
deposition of a biologically relevant antiprotease. Here, we report results of a 3-week phase 
2a study conducted to evaluate the safety and tolerability of inhaled Alpha-1 Hydrophobic 
Chromatography Process (HC) in patients with CF.
Subjects and Methods
Subjects
This study enrolled men and women aged ≥18 years with CF, as evidenced by 1 or more 
clinical features consistent with the CF phenotype and 1 or both of the following: (1) sweat 
chloride level ≥60 mEq/L by quantitative pilocarpine iontophoresis test; (2) 2 well-
characterized mutations in the CF transmembrane conductance regulator (CFTR) gene. 
Subjects were required to have a prebronchodilator forced expiratory volume in 1 second 
(FEV1) ≥40% of predicted at screening and have a FEV1 that was ≥40% of predicted and 
within ±15% of the screening FEV1 value prior to study drug administration on day 1 of the 
study.
Key exclusion criteria included an investigator-defined pulmonary exacerbation either 4 
weeks before screening or between screening and randomization that required antibiotic 
treatment; respiratory insufficiency; significantly elevated liver enzymes; history of 
smoking; any lung surgery; positive culture for Burkholderia cepacia or mycobacterium; or 
active allergic bronchopulmonary aspergillosis. Other major exclusions used in this study are 
provided in the supplementary material.
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Study design and procedure
This was a multicenter, sequential dose escalation, randomized, double-blind, placebo-
controlled phase 2a study (ClinicalTrials.gov: NCT01684410). Alpha-1 HC (100 mg and 
200 mg) was administered once daily and compared with placebo over a 21-day treatment 
period. All subjects provided written informed consent. The study was approved by the 
institutional review board and conducted in accordance with the International Conference on 
Harmonisation guidelines for Good Clinical Practice and the Declaration of Helsinki [19, 
20].
Two sequential dosing cohorts (100 mg and 200 mg) were enrolled (Figure S1). In each 
cohort, subjects were randomized in a 2:1 ratio utilizing a block size of 3 to receive Alpha-1 
HC (50 mg/ml) or a volume-matched placebo delivered once daily via the AKITA2 nebulizer 
system. Inhalation data (eg, start of inhalation, duration of treatment, daily dose compliance) 
was recorded by the AKITA2 device. Subjects were considered adherent to study medication 
if they had taken at least 80% of the prescribed dose over the total duration of study drug 
dosing. A review of unblinded safety results from the Alpha-1 HC 100 mg treatment cohort 
was conducted by the Cystic Fibrosis Foundation Therapeutics Data Monitoring Committee 
prior to proceeding to the next cohort. Screening occurred 14 ± 7 days prior to study 
treatment initiation. A follow-up visit occurred approximately 28 days following the 
treatment period in each cohort.
Safety assessments
Data were collected for evaluation of safety from the time of consent until the final study 
visit. A detailed description of treatment-emergent adverse event (TEAE) and serious 
adverse event (SAE) data collection are provided in the supplementary material.
Subjects were monitored via weekly telephone calls. Pulmonary exacerbations were graded 
as mild (increase in 1 or more symptoms [dyspnea, cough, and/or sputum] that was 
controlled by increasing usual medication), moderate (required outpatient antibiotic 
treatment) and severe (resulted in hospitalization). Subjects treated with Alpha-1 HC were 
tested for immunogenicity with an antibody screening enzyme-linked immunosorbent assay 
to alpha1-PI at screening, study day 22, and at follow-up. Abnormal test values that were 
judged relevant by the investigator were considered adverse events (AEs). Adverse events, 
which were related to the AKITA2 nebulizer system, were reported based on the 
investigator’s judgment (see supplementary material).
Exploratory efficacy variables
The exploratory objectives included possible signals of treatment efficacy, subject 
satisfaction with aerosol treatment, and health-related quality of life (HRQOL). The 
exploratory variables included assessment of changes from baseline following treatment for 
pulmonary function tests (PFTs; FEV1, FEV1% predicted, and forced vital capacity [FVC]), 
and sputum analyses of alpha1-PI levels, NE activity, bacterial culture, leukotriene B4 
(LTB4) concentration, inflammatory cell counts (absolute and differential counts), pro-
inflammatory cytokines (interleukin [IL]-6, -8, and -17; IL-1 beta, and tumor necrosis factor-
alpha [TNF-α]), and urine markers of lung injury (desmosine and isodesmosine).
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Sputum for alpha1-PI level, sputum biomarkers of inflammation and blood biomarkers of 
inflammation were collected at screening, randomization (day 1), day 10, at the end of 
treatment (day 22), and at the end of the 4-week follow-up phase. Urine samples were 
collected at screening, day 10, at the end of treatment, and at follow-up. Forced expiratory 
volume in 1 second and FVC were assessed at screening; before and after daily treatment on 
days 1, 2, and 10 during the 3-week treatment period; at the end of treatment (day 22); and 
after a 4-week follow-up period. The Subject Satisfaction Survey regarding the aerosol 
treatment and the Cystic Fibrosis Questionnaire-Revised (CFQ-R) [21] were assessed by a 
written questionnaire. The Subject Satisfaction Survey was completed at the end of 
treatment visit and a by-subject list of responses to each question was analyzed by treatment 
group and overall. The CFQ-R was completed at randomization and the end of treatment 
visit (day 22). CFQ-R scores and the change from baseline in scores were analyzed by 
treatment group for each domain.
Statistical analyses
Thirty subjects were analyzed via 3 defined populations: safety population (subjects that 
received any dose of study drug), intent-to-treat population (all randomized subjects), and 
per-protocol population (subjects who were randomized, completed investigational product 
treatment, had no major protocol deviations affecting sputum analysis, and had both baseline 
and end-of-study sputum results). For the purpose of analysis, placebo subjects from both 
cohorts were pooled and all analyses were summarized by 3 treatment groups (Alpha-1 HC 
100 mg, Alpha-1 HC 200 mg, and placebo).
Descriptive statistics including the number of subjects, mean, median, standard deviation 
(SD), and minimum/maximum values were analyzed for quantitative variables. The number 
and percentage of subjects in each category were analyzed for categorical/ordinal variables.
Results
Disposition, demographics, and other baseline characteristics of subjects
The disposition of subjects is presented in Figure 1. All subjects were ≥80% adherent with 
study treatment as recorded by AKITA2 device. Demographic and baseline characteristics 
were similar across the 3 treatment groups (Table 1).
Safety
Assessments of adverse events—Treatment-emergent AEs were generally similar 
across all treatment groups (Table 2). Treatment emergent AEs judged by the investigator as 
related to Alpha-1 HC were experienced by 5 subjects (50%) in the Alpha-1 HC 100 mg 
treatment group, 1 subject (10%) in the Alpha-1 HC 200 mg treatment group, and 2 subjects 
(20%) in the placebo treatment group. AKITA2-related TEAEs were observed in 2 (20%) 
subjects (4 TEAEs) in the 100 mg Alpha-1 HC group, 1 (10%) subject (2 TEAEs) in the 
placebo group, and no subjects in the 200 mg Alpha-1 HC group. Serious AEs were reported 
by 1 subject in each treatment group: a pulmonary exacerbation was experienced by a 
subject in each of the Alpha-1 HC 100 mg and placebo treatment groups, both during the 
off-treatment follow-up phase and treated with inpatient antibiotic therapy. Abdominal pain 
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was reported as a TEAE in a subject 8 days after receiving Alpha-1 HC 200 mg. All 3 SAEs 
were moderate in intensity with abdominal pain (Alpha-1 HC 200 mg) and 1 pulmonary 
exacerbation (Alpha-1 HC 100 mg) described by the investigator as “not related” to the 
study drug and the other pulmonary exacerbation (placebo) considered “unlikely” due to the 
study drug. All 3 SAEs were considered not related to the AKITA2 device by the 
investigator and were resolved following hospitalization. No subject discontinued from the 
study due to a TEAE and no deaths occurred.
Most frequent adverse events—The majority of TEAEs occurred only once within a 
treatment group with the most frequent TEAEs experienced in the respiratory, thoracic, and 
mediastinal disorders system organ class (Table 2). The most frequent TEAEs were 
hemoptysis, cough, wheezing, and pulmonary exacerbation (Table 2). A single pulmonary 
exacerbation was reported by 1 subject each (1/10, 10%) in the Alpha-1 HC 100 mg and 
placebo treatment groups and 3 subjects (3/10, 30%) in the Alpha-1 HC 200 mg treatment 
group.
Pulmonary exacerbations and clinical findings—The number of subjects with 
TEAEs—including pulmonary exacerbations, which were mild or moderate in intensity—
was similar across treatment groups with at least 1 mild TEAE experienced by 7 subjects 
(7/10, 70%) in the Alpha-1 HC 100 mg treatment group, 5 subjects (5/10, 50%) in the 
Alpha-1 HC 200 mg treatment group, and 4 subjects (4/10, 40%) in the placebo treatment 
group. Three subjects each in the Alpha-1 HC 100 mg (3/10, 30%) and 200 mg (3/10, 30%) 
treatment groups and 2 subjects (2/10, 20%) in the placebo treatment group experienced 
moderate TEAEs.
There were a total of 5 pulmonary exacerbations: 1 subject each (1/10, 10%) in the placebo 
and Alpha-1 HC 100 mg treatment groups and 3 subjects (3/10, 30%) in the Alpha-1 HC 
200 mg treatment group. Two subjects, both in the Alpha-1 HC 200 mg treatment group, 
experienced pulmonary exacerbations as defined by the investigator’s judgment; all 
remaining pulmonary exacerbations were defined by the Fuchs criteria [22]. As previously 
noted, 2 pulmonary exacerbations were reported as SAEs. No pulmonary exacerbations were 
graded severe by investigators and none resulted in early discontinuation. All pulmonary 
exacerbations were reported during the off-treatment follow-up period.
There were no clinically meaningful mean changes from baseline at any time point for 
clinical laboratory values, vital sign measurements, and physical exam findings (see 
supplementary materials).
Pulmonary function tests—Overall, no clinically meaningful mean changes from 
baseline in PFT values were identified (Table 3). Two subjects, both in the Alpha-1 HC 200 
mg treatment group, exhibited a ≥20% decline in FEV1 from baseline. One subject had a 
≥20% decline in FEV1 from baseline on study day 1 at 15 minutes and 1.5 hours postdose 
that resolved within 4 hours of receiving study drug. The second subject exhibited a ≥20% 
decrease in FEV1 at the end-of-treatment visit (study day 22) but did not have any other 
postbaseline FEV1 that was ≥20% lower than the baseline FEV1. A single subject in the 
placebo treatment group had a TEAE of PFT decrease on follow-up that was reported as 
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mild in intensity and not related to the study drug or AKITA2 device. No clinically relevant 
changes from baseline in peak flow measurement were recorded and none of the subjects 
recorded a postbaseline peak flow that was ≤30% of the baseline value.
Viral safety and immunogenicity—During the study, no subject tested positive for 
hepatitis A, B, or C; human immunodeficiency virus; or parvovirus B19 infection; and there 
were no reports of subjects exhibiting clinical signs and/or symptoms of viral infection. One 
subject administered Alpha-1 HC was positive for nonneutralizing anti-Alpha-1 HC 
antibodies, and this immunogenic response was determined to be transient in follow-up 
testing and did not lead to the development of any symptoms.
Exploratory variables—Pulmonary function tests provided both safety and exploratory 
efficacy endpoints in this study. No clinically meaningful changes were observed in these 
subjects (Table 3). Sputum analysis showed a notable increase in the alpha1-PI level 
following study drug administration at randomization and study day 10 in the Alpha-1 HC 
treatment groups but not in the placebo treatment group. A larger increase in the mean 
sputum alpha1-PI level was observed in the higher-dose (200 mg) treatment group (Table S1, 
Figure 2), suggesting a trend across doses. There were no notable differences between 
treatment groups or consistent trends over time in any treatment group for any other sputum 
parameters (NE activity, LTB4, IL-6, -8, and -17; IL-1 beta, and TNF-α) (Table S2) and 
inflammatory cell counts. Similarly, serum alpha1-PI, blood inflammatory biomarkers (TNF-
α, IL-6, IL-8, and IL-10) and urine desmosine and isodesmosine showed no noteworthy 
changes over time.
By a written questionnaire, most subjects (21/30) rated their effort to inhale from the 
AKITA2 inhalation system as “normal” (11/30), “fairly easy” (6/30), or “very easy” (4/30). 
Most subjects (83.3%, 25/30) rated the airflow administered by the AKITA2 device as 
“appropriate” and a majority of subjects (90%, 27/30) felt that the time to administer 
treatment with the AKITA2 was “just right” and “somewhat quick.” However, a small 
percentage of subjects (10%, 3/30) felt that the time to administer treatment with the 
AKITA2 device was “too long.” The actual recorded inhalation times for the 100 mg and 
200 mg doses were 9.6 minutes and 15.1 minutes, respectively. The HRQOL assessed by 
CFQ-R completed by subjects at randomization and end-of-treatment visit showed no 
apparent quality-of-life differences, trends, or mean changes of note in total score or domain 
scores between treatment groups and within any treatment group.
Discussion
The results from the study provide important data supporting the safety of Alpha-1 HC 
administered for 21 days in subjects with CF. Although AEs were observed in the Alpha-1 
HC and placebo treatment groups, none were dependent on the dose or showed consistent 
treatment dependency. Furthermore, TEAEs were mild or moderate in severity with no study 
discontinuations due to TEAEs. Of the 3 SAEs reported, only 1 (abdominal pain) started 
during the treatment phase with the actual hospitalization occurring 16 days after completion 
of the study treatment. The most frequent TEAEs were similar in the Alpha-1 HC and the 
placebo treatment groups, which suggests that Alpha-1 HC at either dose was safe and well 
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tolerated during the duration of the study by the subjects with CF. Other safety parameters 
reported as TEAEs—including physical examination findings, PFT measurements, 
laboratory tests, and vital signs—were not clinically meaningful for any treatment group and 
were not considered to be related to study drug.
Importantly, the delivery of inhaled Alpha-1 HC was reflected by increased alpha1 
antitrypsin levels in the sputum of patients, with a trend toward higher levels at the higher 
dose. These results strongly suggest the stability of the compound postnebulization and 
demonstrate that an electronically regulated nebulizer system such as the AKITA2 device 
can effectively deliver Alpha-1 HC by aerosol in CF subjects, consistent with similar prior 
studies [4, 12]. The AKITA2 inhalation system was well accepted by the subjects as 
indicated by survey results.
Aerosolized alpha
-1-PI has been shown to increase alpha1-PI levels and decrease NE levels 
in subjects with CF [4, 6]. Although Alpha-1 HC did not reduce NE activity in the current 
study; unlike previous studies, this trial was not adequately powered to identify a decrease in 
NE activity [4], nor did it measure NE levels in the epithelial lining fluid, which is a more 
direct measure of active neutrophil elastase [6]. The inability to detect changes in blood and 
sputum inflammatory biomarkers as well as the breakdown products of NE in the urine 
(desmosine and isodesmosine) may be due to the short study duration as well as the small 
amount of Alpha-1 HC reaching the systemic circulation.
The current study was not powered to assess changes in FEV1 or sputum alpha1 antitrypsin 
(A1AT) concentrations; however, subsequent phase 2 and phase 3 studies could be 
sufficiently powered to analyze these parameters. Other opportunities for further phase 2 and 
phase 3 studies include a longer duration safety evaluation period, inclusion of patients with 
more severe respiratory insufficiency, and the delivery of Alpha-1 HC via alternative 
delivery devices.
In conclusion, daily Alpha-1 HC (100 mg or 200 mg) delivered for 3 weeks was safe, well 
tolerated, well accepted, and effective in raising the alpha1-PI levels in the sputum of 
subjects with CF. These promising results suggest that Alpha-1 HC is effectively and safely 
delivered in patients with CF. However, future studies are needed to determine efficacy and 
potential use of Alpha-1 HC for chronic therapy in CF lung disease.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Subject Disposition.
aDue to pulmonary function tests, pulmonary exacerbations, and problems with pretreatment 
sputum collection as defined in the inclusion/exclusion criteria.
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Figure 2. 
Increase in the Alpha1-PI Level in Sputum of Subjects Treated with Alpha-1 HC.
A1AT, alpha1 antitrypsin.
O, mean; —, median within bars; *, outlier; boxes represent the range of 25%–75%.
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Table 1
Subject Demographic and Baseline Characteristics.
Characteristic Alpha-1 HC
100 mg
(n = 10)
Alpha-1 HC
200 mg
(n = 10)
Placebo
(n = 10)
Sex, n (%)
  Female 8 (80) 6 (60) 6 (60)
Age, y
  Mean (SD) 28.2 (10.6) 28.1 (11.4) 29.3 (10.0)
Race, n (%)
  White 10 (100) 9 (90) 10 (100)
  Multiracial 0 1 (10) 0
BMI (kg/m2)
  Mean (SD) 23.7 (5.5) 22.3 (2.2) 22.3 (4.1)
Patient with known genetic mutation, n (%)
  Yes 9 (90) 10 (100) 10 (100)
  No 1 (10) 0 0
Ever had a pulmonary exacerbation that required IV antibiotics, n (%)
  Yes 10 (100) 10 (100) 8 (80)
  No 0 0 2 (20)
Positive respiratory culture
within last 12 months, n (%)
10 (100) 10 (100) 10 (100)
FEV1% predicted
  Mean (SD) 68.2 (21.51) 69.5 (24.94) 71.1 (21.71)
BMI, body mass index; FEV1, forced expiratory volume in 1 second; SD, standard deviation.
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Table 2
Summary of subjects with AEs, most frequent AEs (≥3 subjects) and drug-related AEs.
Alpha-1 HC
100 mg
(n = 10)
Alpha-1 HC
200 mg
(n = 10)
Placebo
(n = 10)
Subjects with at least 1 TEAE 10 (100) 8 (80) 6 (60)
Subjects with drug-related TEAEs 5 (50) 1 (10) 2 (20)
Subjects with AKITA2-related TEAEs 2 (20) 0 1 (10)
Subjects with SAEs 1 (10) 1 (10) 1 (10)
Subjects with TEAE leading to
discontinuation
0 0 0
Most frequent TEAEs occurring in ≥3 subjects within 1 treatment group
Hemoptysis 4 (40) 1 (10) 1 (10)
Cough 3 (30) 1 (10) 1 (10)
Wheezing 3 (30) 1 (10) 0
Pulmonary exacerbation 1 (10) 3 (30) 1 (10)
Drug-related TEAEs
Total number of drug-related TEAEs 7 3 4
Subjects with ≥1 drug-related TEAEs 5 (50) 1 (10) 2 (20)
Bronchospasm 0 0 1 (10)
Cough 0 0 1 (10)
Dry throat 1 (10) 0 0
  Dyspnea 1 (10) 0 0
Hemoptysis 1 (10) 0 0
Oropharyngeal pain 0 0 1 (10)
Pulmonary exacerbation 0 1 (10) 0
Respiratory tract irritation 1 (10) 0 0
Sputum increased 1 (10) 0 1 (10)
Wheezing 1 (10) 0 0
Otitis externa 0 1 (10) 0
Otitis media 0 1 (10) 0
Decreased appetite 1 (10) 0 0
AE, adverse event; SAE, serious adverse event; TEAE, treatment-emergent adverse event.
Data presented as n (%).
Adverse events were linked to system organ class and preferred term by the Medical Dictionary for Regulatory Activities, Version 15.0. Subjects 
who had more than 1 event within a body system or assigned to the same preferred term were counted once.
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